BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
S Sammons, AED Van Swearingen, L Noteware, NA Bagegni, K Moulton, S Threatt, D Jaggers, S Shea, ES Lipp, E Riley, S Jung, G Broadwater, M Ross, K Strickland, S Beyer, A Conlin, A Morikawa, R Murthy, CK Anders
Trial Locations
All sites in which the trial HCRN-BRE21-516 being conducted in.
